LEUVEN, Belgium, July 20, 2016 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG) publishes today the transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.
Summary of the notification
On July 19, 2016, TiGenix NV received a transparency notification from Cormorant Asset Management, LLC, following the acquisition of shares on March 14, 2016 by two entities controlled by it (i.e., Cormorant Global Healthcare Master Fund, LP and CRMA SPV, LP) after which Cormorant Asset Management, LLC has the discretionary power to exercise 11,756,894 voting rights in TiGenix NV (5.81% of the voting rights). As a result the 5% threshold was crossed.
Content of the notification by Cormorant Asset Management, LLC
Date of the notification: July 19, 2016.
Reason of the notification: acquisition of shares.
Person subject to the notification requirement: Cormorant Asset Management, LLC, who is a person that notifies alone.
Date on which the threshold was crossed: March 14, 2016.
Threshold that was crossed: 5%.
Details of the notification: following the acquisition of shares, the number of voting rights was as follows:
- Cormorant Asset Management, LLC holds 11,756,894 voting rights in TiGenix NV (5.81% of voting rights).
Chain of controlled undertakings through which the holdings are effectively held: Cormorant Asset Management, LLC is not a controlled entity. Cormorant Asset Management, LLC has received the discretionary power to exercise the voting rights of 11,756,894 TiGenix shares from the following two entities, which are both controlled by it: Cormorant Global Healthcare Master Fund, LP and CRMA SPV, LP.
This press release and the above-mentioned transparency notifications can be consulted on our website:
- press release: http://www.tigenix.com/en/pages/11/2016;
- notifications: http://www.tigenix.com/en/page/26/shareholders.
For more information:
Chief Financial Officer
T: +34 91 804 92 64
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic cardiac indication. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com.